| Urocortin 2 infusion in human heart failure. | |
| | |
MedLine Citation:
|
PMID: 17720993 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To document the haemodynamic, neurohormonal, and renal responses to Urocortin 2 (UCN2) infused in human heart failure (HF). METHODS AND RESULTS: Eight male patients with HF [left ventricular ejection fraction (LVEF) < 40%, NYHA class II-III] received placebo and 25 [low dose (LD)] and 100 microg [high dose (HD)] of UCN2 intravenously over 1 h in a single-blind, placebo-controlled, dose-escalation design. UCN2 increased cardiac output (CO) (mean peak increments +/- SEM; placebo 0.3 +/- 0.1; LD 1.0 +/- 0.3; HD 2.0 +/- 0.2 L/min; P < 0.001) and LVEF (0.0 +/- 1.5; LD 5.9 +/- 2.1; HD 14.1 +/- 2.7%; P = 0.001) and decreased mean arterial pressure (placebo 6.7 +/- 1.3; LD 11.4 +/- 1.7; HD 19.4 +/- 3.3 mmHg; P = 0.001), systemic vascular resistance (SVR) (placebo 104 +/- 37; LD 281 +/- 64; HD 476 +/- 79 dynes s/cm(5); P < 0.003), and cardiac work (CW) (placebo 48 +/- 12; LD 66 +/- 22; HD 94 +/- 13 mmHg/L/min; P < 0.001). No significant effect on vasoconstrictor/volume-retaining neurohormones was noted. UCN2 decreased urinary volume (P = 0.035) but not creatinine excretion (P = 0.962). CONCLUSION: Intravenous UCN2 in HF induced increases in CO and LVEF with falls in SVR and CW. No hormone response occurred. The role of UCN2 in circulatory regulation and its potential therapeutic application in heart disease warrant further investigation. |
| | |
Authors:
|
Mark E Davis; Christopher J Pemberton; Timothy G Yandle; Steve F Fisher; John G Lainchbury; Christopher M Frampton; Miriam T Rademaker; Mark Richards |
Related Documents
:
|
17353513 - Direct renin inhibition with aliskiren in obese patients with arterial hypertension. 21270813 - Blood pressure components and risk for chronic kidney disease in middle-aged japanese m... 8935023 - Pressure waves in root canals induced by nd: yag laser. |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2007-08-25 |
Journal Detail:
|
Title: European heart journal Volume: 28 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-11-02 Completed Date: 2008-06-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: England |
Other Details:
|
Languages: eng Pagination: 2589-97 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch 8140, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Cardiotonic Agents / administration & dosage, pharmacokinetics, pharmacology* Dose-Response Relationship, Drug Heart Failure / drug therapy*, physiopathology Hemodynamics / drug effects Humans Kidney / drug effects Male Middle Aged Single-Blind Method Urocortins / administration & dosage, pharmacokinetics, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Urocortins |
| Comments/Corrections | |
Comment In:
|
Eur Heart J. 2007 Nov;28(21):2561-2
[PMID:
17905792
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Incidence of biopsy-proven glomerulonephritis.
Next Document: Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hy...